XML 34 R14.htm IDEA: XBRL DOCUMENT
v3.24.0.1

REVENUE | 12 Months Ended
--- | ---
Dec. 31, 2023
REVENUE |
REVENUE | NOTE 8 - REVENUE The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended December 31,
(U.S. dollars in thousands) | ​ | 2021 | ​ | 2022 |  | 2023
Pfizer | ​ | $ | 10,160 | ​ | $ | 12,403 | ​ | $ | 12,522
Brazil | ​ | $ | 6,400 | ​ | $ | 9,452 | ​ | $ | 10,401
Chiesi | ​ | ​ | 189 | ​ | $ | 3,437 | ​ | $ | 17,495
Total revenues from selling goods | ​ | $ | 16,749 | ​ | $ | 25,292 | ​ | $ | 40,418
Revenues from license and R&D services | ​ | $ | 21,601 | ​ | $ | 22,346 | ​ | $ | 25,076
​ During the year ended December 31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration